This month, I presented the Clinical Trial Risk Tool at the Plotly Dash in Action webinar. I was interviewed by Plotly’s Community Manager Adam Schroeder. You can watch the relevant part of the webinar below.
The Clinical Trial Risk Tool was one of four interactive apps presented as part of the webinar. The speakers at the webinar were:
Screenshot of Matteo Trachsel’s Thermoplan dashboard which calculates the carbon footprint of coffee machine usage.
Screenshot of Agah Karakuzu’s dashboard which allows neuroscientists to assess the reproducibility of T1 values across different sites and vendors where researchers used the same research protocol. (T1 is the time it takes water molecules in the brain to return to their original state following a magnetic pulse).
If you would like to cite the tool alone, you can cite:
Wood TA and McNair D. Clinical Trial Risk Tool: software application using natural language processing to identify the risk of trial uninformativeness. Gates Open Res 2023, 7:56 doi: 10.12688/gatesopenres.14416.1.
A BibTeX entry for LaTeX users is
@article{Wood_2023, doi = {10.12688/gatesopenres.14416.1}, url = {https://doi.org/10.12688%2Fgatesopenres.14416.1}, year = 2023, month = {apr}, publisher = {F1000 Research Ltd}, volume = {7}, pages = {56}, author = {Thomas A Wood and Douglas McNair}, title = {Clinical Trial Risk Tool: software application using natural language processing to identify the risk of trial uninformativeness}, journal = {Gates Open Research} }
Guest post by Safeer Khan, Lecturer at Department of Pharmaceutical Sciences, Government College University, Lahore, Pakistan Introduction The success of clinical studies relies heavily on proper financial planning and budgeting. These processes directly impact key factors such as project timelines, resource allocation, and compliance with regulatory requirements. The accurate forecasting of costs for clinical trials, however, is a highly complex and resource-intensive process. A study by the Tufts Center for the Study of Drug Development found that the average cost of developing a new drug is approximately $2.
Guest post by Safeer Khan, Lecturer at Department of Pharmaceutical Sciences, Government College University, Lahore, Pakistan Introduction Recent years have seen a substantial rise in oncology clinical trials, with annual growth exceeding 260 studies on average [1]. Despite this increase, these studies continue to be some of the most demanding and resource-intensive in clinical research. The combination of intensive monitoring, detailed assessment schedules, and highly specific eligibility criteria creates substantial operational challenges.
Guest post by Safeer Khan, Lecturer at Department of Pharmaceutical Sciences, Government College University, Lahore, Pakistan Introduction In recent years, the cost of conducting clinical trials has risen dramatically. This increase has posed a significant challenge for pharmaceutical companies, researchers, and healthcare innovators. According to a study published in Nature Reviews in 2017, the median cost of conducting a study was $3.4 million for phase I trials, $8.6 million for phase II trials, and $21.
